3 days popular7 days popular1 month popular3 months popular

Stereotactic Ablative Radiotherapy Effective Treatment For Non-Small Cell Lung Cancer

Until recently, many elderly patients with stage I non-small cell were left untreated because treatment may not improve their quality of life. However, stereotactic ablative () has become one of the standards of treatment for these patients. The given over a two-week period allows frail patients to undergo the treatment.

Researchers wanted to know if this treatment maintained the same health-related qualify of life levels as patients receiving surgery. The researchers received questionnaires from 382 patients treated with SABR from 68 centers in The Netherlands. The questionnaire asked patients to rate things like physical function, appetite loss, pain and emotional function.

The study, presented in the July 2012 issue of the for the Study of Lung Cancer’s () Journal of Thoracic Oncology, concluded that the health-related quality of life in these patients does not seem to be negatively affected.

The authors conclude that in contrast to patients who underwent surgery, measures of qualify of life scores including a range of functional and symptom outcomes did not deteriorate in the first two years after SABR.

Source

The lead author of this work is Dr. Frank Lagerwaard. Co-authors include IASLC members Dr. Cornelis Haasbeek, Dr. and Prof. Ben Slotman and Prof. Suresh Senan.
International Association for the Study of Lung Cancer